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Abstract 
A  63-year-old  female  with  a  well-vascular-
ized pulmonary metastasis of an endometrial
stromal  sarcoma  (ESS)  of  6¥6  cm  received
selective  embolization  with  150-250  mm
polyvinyl alcohol (Contour; Boston Scientific,
Natick, MA, USA) via a bronchial artery. Post-
interventional loss of perfusion was qualita-
tively estimated to be >80%. The lesion was
located in direct proximity to the pulmonary
hilar vessels. Owing to recurrent and sudden
hemoptyses, an interdisciplinary tumor board
assessed the risk of life-threatening blood loss
to be greater than that of angiography with
particle  embolization  and  agreed  on  an
endovascular  approach.  Hemoptysis  did  not
recur  in  a  follow-up  period  of  six  months.
Initial clinical symptoms were noted 25 years
ago. However, establishing a definite diagno-
sis has, for a long time, remained a histopatho-
logical challenge.
Introduction
Endometrial  stromal  sarcomas  (ESS)  are
rare and account for only 0.2% of all malignant
uterine tumors.
1 Apart from typical local recur-
rences in the pelvic area, metastases of the
lung are common. Reported incidences range
from 7-28%.
2 Metastases of ESS (especially to
the lung) may occur decades after resection of
the primary tumor.
1,3 In general, methods like
image-guided  embolization
4-6 and  radiofre-
quency  ablation
7 are  employed  increasingly
and refined
8 in managing pulmonary tumors.
To our knowledge, the response of pulmonary
metastases of ESS to embolization has not yet
been described. A review of the existing litera-
ture provided neither a description of how to
proceed,  should  pulmonary  metastasis  of  an
ESS induce hemoptysis, nor whether selective
polyvinyl alcohol embolization may be an effective
and feasible approach.
Case Report
Twenty-five  years  ago,  our  patient  had
undergone a hysterectomy because of an uter-
ine  leiomyoma,  followed  by  an  atypical  lung
resection in 1993 owing to metastases of an
unknown primary. The primary was suspected
to be a schwannoma, which then progressed to
become  a  neurosarcoma.  Hormone  therapy
with tamoxifen was discontinued in 1994. In
1998, the patient was diagnosed with multiple
diffuse pulmonary lesions, most likely second-
ary  to  leiomyomatosis.  In  2008,  a  surgical
resection of the left inferior lobe of the lung
was performed because of a progressive cav-
ernous  lesion.  Tuberculosis  was  ruled  out
beforehand  and,  computerized  tomography
(CT)-morphologically,  the  lesion  was
enhanced after contrast medium application,
indicating  an  intense  vascular  supply.  The
lesion was further histo-morphologically pecu-
liar, as it was found to be an estrogen and pro  -
gesterone  receptor-positive  spindle  cell  neo-
plasm with recent and older hemorrhagic com-
ponents.  Even  after  discussion  with  several
universities’ pathology departments’ advisory
boards,  the  diagnosis  remained  indefinite;
however, a metastasis of an ESS was favored.
Given  the  morphology,  the  existence  of  pul-
monary metastases,
9 and the immune-expres-
sion  profile,  the  differential  diagnosis  of  a
hemangioperycytoma was also considered. Yet,
in a published study describing eight cases,
10
all hemangioperycytomas were estrogen recep-
tor negative. A bilateral salpingovarectomy in
2008 revealed no signs of malignancy.
The  63-year-old  female  presented  with
recurrent, infrequent, and sudden hemoptysis
of  about  200  mL.  A  CT  scan  of  the  thorax,
abdomen, and pelvis in 2009 revealed progres-
sive metastases of up to 6¥6 cm in the left
lung, directly adjacent to the heart and pul-
monary hilar vessels (Figure 1), as well as of
up to 20 mm in diameter in the paratracheal
lymph nodes in the vicinity of the pulmonary
vasculature. Moreover, a lesion of 6¥4 cm was
detected  in  the  sacral  bone  with  cortical
destruction and infiltration of the spinal canal
(Figure 2). The CT scan depicted no hemor-
rhagic effusion. Given the recurrent and sud-
den hemoptyses and the progressive expansive
character of the well-vascularized pulmonary
lesion,  an  interdisciplinary  tumor  board
assessed the risk of life-threatening blood loss
to be greater than that of angiography with
particle  embolization  and  agreed  on  an
endovascular approach. By then blood loss was
estimated to amount to ca. 300 mL per assault
and occurred about twice weekly.
The  angiography  before  embolization
depicted  a  moderately  hypertrophied  left
bronchial  artery  supplying  the  pulmonary
lesion.  Its  branches  tapered  as  they
approached the metastasis (Figure 3A and B).
They then appeared to fill a collection of abnor-
mally dilated vessels, especially adjacent to the
superior aspect of the mass. The correspond-
ing CT (Figure 1) depicted a heterogeneous
lesion of irregular vascularization, indicating
distortion of the supplying pulmonary artery
branches.  Imaging  revealed  no  evidence  of
focal aneurysm formation owing to tumor infil-
tration. The embolization was performed via
selective placement of a 5 F SPECIAL angio-
graphic catheter (Cordis Europe, Roden, NL).
Bronchial  arterial  particle  embolization  was
performed  with  injection  of  150-250  µm
polyvinyl alcohol (Contour; Boston Scientific,
Natick, MA, USA). Post-interventional controls
confirmed the loss of lesion perfusion to be
>80%  (Figure  3C  and  D).  A  super-selective
microcatheter was not necessary, as the pul-
monary target lesion was sufficiently targeted
with the 5 F angiographic catheter. Clinical fol-
low-up six months later revealed no recurrence
of hemoptysis as well as tumor size reduction
in CT scans and conventional X-rays from 6¥6
cm to 4¥4 cm after polyvinyl alcohol emboliza-
tion (Figure 4 A and B).
Discussion
The tumor entity of ESS is not well under-
stood,  especially  concerning  its  development
and growth. Because estrogen receptors seem
to be commonly expressed, hormonal growth
pathways  appear  to  play  a  key  role  in  the
tumor’s progression.
11 ESS can be traditionally
classified into high- and low-grade, depending
primarily  on  cytological  differentiation  and
morphological features; and not – as often stat-
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12 The  2003  WHO
classification  differentiates  between  stromal
sarcomas of the endometrium, corresponding
with  low  malignant  stromal  sarcomas,  and
undifferentiated  sarcomas  of  the  endomet  -
rium, which covers a group of highly malig-
nant  polymorph  cells.
13 About  50%  of  all
patients with low-grade ESS seem to develop
recurrences, typically in the form of pulmonary
and  pelvic  metastases.  Only  very  few  cases
with  skeletal  involvement  have  been  report-
ed.
1,14 Cases with the primary diagnosis of ESS
in extra-uterine locations such as the vulva,
vagina,  ovaries,  abdominal  cavity,  and
retroperitoneal  space  are  very  rare.
15 ESS  is
often  associated  with  endometriosis  and/or
hyperestrogenism.  Endogenous  hyperestro-
genism  may  be  induced  either  locally  by
endometriotic tissue, or systemically by preg-
nancy  or  polycystic  ovarian  syndrome.
Exogenous hyperestrogenism can occur as a
side-effect  of  ovulation-stimulating  drugs.
Endometriosis has been proposed as a precur-
sor of low-grade ESS, thus offering an explana-
tion  for  extra-uterine  primary  or  secondary
tumors.
15,16
Multiple  well-demarcated  lesions  with
entrapped  air  surrounded  by  non-neoplastic
respiratory epithelium are characteristic of the
most  common  morphological  pattern  of  pul-
monary  ESS  metastases.
2 Several  unusual
morphological patterns exist including solitary
lesions with infiltrative margins, lymphangitic,
cystic,  or  even  micronodular
17 morphology.
These aspects may impede a correct diagnosis,
sometimes  mimicking  lymphangioleiomyo-
matosis, for example. In our case, the patho  -
logy  department  was  able  to  exclude  lymph  -
angioleiomyomatosis as a possible differential
diagnosis.  Furthermore,  the  pathologists
excluded a pulmonary origin of the assessed
lung lesions.
Owing  to  an  arboreal  vasculature  and  an
undifferentiated  appearance  of  the  tumor
cells, endometrial stromal sarcomas are easily
mistaken  for  several  other  soft-tissue  neo-
plasms.
10 Unfortunately,  misdiagnosis  as  a
benign  uterine  tumor  is  not  uncommon  in
patients  with  ESS.
3 However,  compared  to
other  possible  differential  diagnoses  with
Figure  1.  A  computerized  tomography
scan slice of the thorax illustrating a pro-
gressive metastasis in the left lung, directly
adjacent to the heart and pulmonary hilar
vessels (arrow).
Figure  2.  A  computerized  tomography
scan  slice  of  the  pelvis  demonstrating  a
lesion  in  the  sacral  bone  (asterisk)  with
cortical destruction and infiltration of the
spinal canal.
Figure 3. (A and B) Angiograms before embolization depicting a moderately hypertro-
phied  left  bronchial  artery  supplying  the  pulmonary  lesion,  with  tapering  branches
approaching the metastasis. (C and D) The post-bronchial arterial particle embolization
angiograms confirm the loss of lesion perfusion.
Figure 4. (A and B) Conventional X-rays showing tumor size reduction after polyvinyl
alcohol embolization within a six month period.
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with ESS may have a more favorable progno-
sis.
18
Conclusions
In a well-vascularized pulmonary metastasis
of  an  ESS,  selective  embolization  with
polyvinyl alcohol via a bronchial artery is an
effective and feasible approach to reduce per-
fusion of the lesion and thus the risk of critical
blood loss. To date (six months after emboliza-
tion), neither has there been a recurrence of
hemoptysis  nor  has  a  further  embolization,
including  percutaneous  radiofrequency  abla-
tion and/or radiation after embolization, been
necessary in our patient.
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